Skip to Main Content

Newsroom

Administrator Verma Statement on FDA’s Biosimilars Action Plan

July
18

"CMS congratulates the FDA on the release of the Biosimilars Action Plan. President Trump has set a clear priority to lower drug prices, and the bold steps in this proposal will do just that, while also expanding access for patients.  CMS and FDA are both working to accelerate innovation in the biosimilars market – CMS has taken action to do so by providing biosimilars with separate payment codes and by lowering the amount of cost sharing that low-income beneficiaries pay for biosimilars.

Learn more about Administrator Verma Statement on FDA’s Biosimilars Action Plan

Administrator Verma Statement on Recent 340B Court Decision

July
18

“I applaud the court for its decision. The court’s ruling is a big win for patients, who this year alone are expected to save $320 million in out-of-pocket expenses for medicines in their doctors’ offices. This policy is providing relief every day from the rising costs of drugs, a top priority for President Trump.”

Learn more about Administrator Verma Statement on Recent 340B Court Decision

CMS Proposes Historic Changes to Modernize Medicare and Restore the Doctor-Patient Relationship

July
12

Today, the Centers for Medicare & Medicaid Services (CMS) proposed historic changes that would increase the amount of time that doctors and other clinicians can spend with their patients by reducing the burden of paperwork that clinicians face when billing Medicare. The proposed rules would fundamentally improve the nation’s healthcare system and help restore the doctor-patient relationship by empowering clinicians to use their electronic health records (EHRs) to document clinically meaningful information, instead of information that is only for billing purposes.

Learn more about CMS Proposes Historic Changes to Modernize Medicare and Restore the Doctor-Patient Relationship

New CMS Proposals to Modernize and Drive Innovation in Durable Medical Equipment and End-Stage Renal Disease Programs

July
11

Today, the Centers for Medicare & Medicaid Services (CMS) proposed innovative changes to the payment rules for Durable Medical Equipment Prosthetics, Orthotics, and Supplies (DMEPOS) and the End-Stage Renal Disease (ESRD) program. The DME proposals in the proposed rule released today aim to increase access to items for patients and simplify Medicare’s DMEPOS Competitive Bidding Program (CBP) to drive competition and increase affordability. The rule also includes ESRD proposals, including a proposal to address new renal dialysis drug and biological costs and foster innovations in treatment by incentivizing new therapies for patients on dialysis and a proposal to reduce facility-related documentation burden.

Learn more about New CMS Proposals to Modernize and Drive Innovation in Durable Medical Equipment and End-Stage Renal Disease Programs

Administrator Verma Statement on the Administration’s Action to Lower Drug Prices

July
11

“President Trump’s bold leadership to lower drug prices is being heard across the nation. Pfizer’s announcement to scale back their recent price increases is a win for all Americans. At CMS, we will continue to increase competition, strengthen negotiations, and lower costs for Medicare and Medicaid beneficiaries. I join Secretary Azar in working with all stakeholders who share the President’s concern for patients and who want to work with us to lower drug prices.”

Learn more about Administrator Verma Statement on the Administration’s Action to Lower Drug Prices


.